AIM ImmunoTech AAQS

Mitä AIM ImmunoTech tekee? AIM ImmunoTech Inc is a biotechnology company based in Ocala, Florida, operating within the health care sector. The company focuses on the clinical development of drug therapies utilizing natural immune system enhancing technologies for treating viral and immune-based disorders. It employs 31 full-time staff members. AIM ImmunoTech's primary products include Alferon N Injection, approved for intralesional treatment of refractory or recurring external genital warts in patients over 18, and Ampligen, which is under clinical development for Chronic Fatigue Syndrome (CFS). The company also develops Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. AIM ImmunoTech went public on July 12, 1996, with its ticker symbol AIM and ISIN US00901B3033. Its website is hemispherx.net. The company's operations are centered around research and development activities related to Ampligen and other drugs in development, alongside sales and marketing of Alferon. The firm's activities are primarily directed toward addressing chronic viral and immune-related conditions through innovative therapeutic approaches. AIM ImmunoTech on yksi Eurpooliin suosituimmista yhtiöistä.